Novel oestrogen sulfamates: A new approach to oral hormone therapy

Expert Opinion on Investigational Drugs

Volumn 7, Issue 4, 1998, Pages 575-589

  Elger, Walter ^a   Palme, Hans Joachim ^a   Schwarz, Sigfrid ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

hepatic activity; oestradiol sulfamate J995; oestrogen sulfamates; oestrogenic activity

Indexed keywords

EID: 85001837381     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.7.4.575     Document Type: Review

References (25)

1. SCHWARZ S, WEBER G: Alkan- und Cycloalkansulfonatedes 17alpha-Athinylöstradiols. J. Prakt. Chem. (1970) 312: 653 – 659.
2. GORETZLEHNER G, RUDOLF B, KLAUSCH W et al.: Orale hormonale Kontrazeption mit Deposiston. Dt. Gesundh -Wesen. (1975) 33: 1553 – 1558.
3. GORETZLEHNER G, RUDOLF K, KLAUSCH B: Orale hor-monale Kontrazeption mit der “Wochenpille” Depo-siston. Zentralbl. Gynäkol. (1974) 96: 1569 – 1576.
4. GUDDATH H, SCHNORR D, DORNER G et al: Die klinische Priifung von Ethinylestradiolsulfonat zur konservativen Therapie des Prostatakarzinoms. Zschr. Urol. Nephrol (1987) 80: 125 – 133.
5. SCHWARZ S, WEBER G, KOHNER F: Sulfamate des 17 -Athinylöstradiols. Z. Chemie. (1970) 10: 299 – 300.
6. STOLZNER W: Tierexperimenteller Beitrag zur Entwicklung estrogener Wirkstoffe. Dissertation B, Friedrich-Schiller-University Jena (1989).
7. CLAUSSEN C: Etythrocyten als Arzneimittelträger - Unter-suchungen mit ausgewählten Estrogenen zur Beladung nach oraler Gabe. Dissertation B, Martin-Luther-Universitat Halle-Wittenberg (1990).
8. ELGER W, SCHNEIDER B, TRILLER et al.: Differential ef-fects of estradiol and estrone versus estriol with re-spect to uterotropic and hepatic estrogenicity. Exp. Endocrinol. (1996) 104: 18.
9. SCHWARZ S, THIEME I, RICHTER M et al.: Synthesis of es-trogen sulfamates: compounds with a novel endocri-nological profile. Steroids (1996) 61: 710 – 717.
10. HEDDEN A, JENSEN EV, PALME HJ et al: Analysis of prodrug nature of oestradiol sulfamate (ES) J995: study of oestrogen receptor (ER) binding and induc-tion of ER synthesis in MCF-7-cells. Exp. Clin. Endocri-nol. (1998) 106.
11. KRATTENMACHER R, KNAUTHE R, PARCZYK K et al.: Es-trogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J. Steroid. Biochem. Mol. Biol. (1994) 48: 207 – 214.
12. SCHNEIDER B, FRANKE E, MATZ S et al.: Orally active es-trogens with reduced effects on bile secretion and bile composition. Exp. Clin. Endocrinol. Diabetes (1997) 105: 78.
13. ZUCHNER J, KRAHL E, REDDERSEN G et al.: Effects oferythrocytes on the hepatic extraction and metabo-lism of estradiol (E) and estradiol sulfamate (ES) in the perfused rat liver. Exp. Clin. Endocrinol. Diabetes (1997) 105: 79.
14. JACOBSOHN GM, SIEGEL ET, JACOBSOHN MK: 17 -estr-adiol transport and metabolism in human red blood cells. J. Clin. Endocrinol Metab. (1975) 40 (2): 177 – 185.
15. KRAHL E, REDDERSEN G, MOLLER K et al.: Studies on the transhepatic transfer of oestradiol sulfamate J995 (ES) and the mechanism of systemic release of oestradiol. Exp. Clin. Endocrinol Diabetes (1996) 104: 127.
16. ZIMMERMANN H, Jenapharm GmbH &Co.KG (1997). (Un-published data.)
17. HELMER OM, GRIFFITH RS: The effect of the administra-tion of estrogens on the renin-substrate (hyper-tensinogen) content on rat plasma. Endocrinology (1952) 51: 421 – 426.
18. FREYSCHUSS B, STAVREUS-EVERS A, SAHLIN L et al.: In-duction of the oestrogen receptor by growth hormone and glucocorticoid substitution in primary cultures of rat hepatocytes. Endocrinology (1993) 133: 1548 – 1554.
19. SAHLIN L, NORSTEDT G, ERIKSSON H: Estrogen regula-tion of the estrogen receptor and insulin-like growth factor I in the rat uterus: a potential coupling between effects of estrogen and IGF-I. Steroids (1994) 59: 421 – 430.
20. ELGER W, SCHWARZ S, HEDDEN A et al.: Sulfamates of various estrogens are prodrugs with increased sys-temic and reduced hepatic estrogenicity at oral appli-cation. J. Steroid. Biochem. Mol. Biol. (1995) 55: 395 – 403.
21. GOLDZIEHER JW: Selected aspects of the pharmacoki-netics and metabolism of ethinyl estrogens and their clinical implications. Am. J. Obstet. Gynecol. (1990) 163: 318 – 322.
22. SCHOULTZ VON B, CARLSTROM K, COLLSTE L et al.: Es-trogen therapy and liver function-metabolic effects of oral and parenteral administration. The Prostate (1989) 14: 389 – 395.
23. MASHCHAK CA, LOBO RA, DOZONO-TAKANO R et al.: Comparison of pharmacodynamic properties of vari-ous estrogen formulation. Am. J. Obstet. Gynecol (1982) 144: 511 – 518.
24. MELAMED M, CASTANO E, NOTIDES AC et al.: Molecular and kinetic basis for the mixed agonist/antagonist ac-tivity of estriol. Mol. Endocrinol (1997) 11: 1868 – 1878.
25. REED MJ, PUROHIT A, HOWARTH NM et al.: Steroid sul-phatase inhibitor: a new endocrine therapy. Drugs Fut. (1994) 19 (7): 673 – 680.